消化系统癌症的抗体治疗方法:过去,现在和未来
Ikrame Dadi1, Thibault Mazard2, Lena-Marie Schmitt1
1Tumor Microenvironment and Resistance to Treatment Laboratory, IRCM, Univ Montpellier, ICM, INSERM, Montpellier, France.
单克隆抗体 (mAbs) 在治疗胃肠道 (GI) 癌症方面取得了重大进展,提供了超越传统化疗的有针对性的方法. 本综述详细介绍了已批准的mAbs,其机制以及改善肠道癌症治疗的未来方向.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 胃肠道 (GI) 癌症是全球癌症相关死亡的主要原因,其中结肠直肠,胃和肝癌最为普遍.
- 对胃肠道恶性瘤的常规化疗缺乏特异性,导致健康组织的显著毒性.
- 癌症生物学方面的进步刺激了向治疗的发展,包括小分子激酶抑制剂 (SMKI) 和单克隆抗体 (mAbs).
研究的目的:
- 审查使用单克隆抗体 (mAbs) 治疗肠胃癌的最新进展.
- 提供临床批准的mAbs的概述,包括它们的点和作用机制.
- 讨论改善mAb基治疗在胃肠道瘤学中的疗效和特异性的策略.
主要方法:
- 关于胃肠道癌症治疗近期进展的文献综述.
- 对临床批准的肠道恶性瘤单克隆抗体 (mAbs) 的分析.
- 基于其治疗点 (癌细胞与瘤微环境) 的mAbs的分类.
主要成果:
- 几种mAbs在临床上已被批准用于治疗各种胃肠道癌症,针对特定的分子变化.
- 单克隆抗体 (mAbs) 表现出多种作用机制,包括直接向癌细胞和调节瘤微环境 (TME).
- 目前正在进行的研究重点是通过技术进步优化mAb的有效性和特异性.
结论:
- 单克隆抗体 (mAbs) 为肠道癌提供了针对性和越来越有效的治疗策略.
- 了解mAbs的具体目标和机制对于优化治疗结果至关重要.
- 未来的mAb技术发展有望进一步改善肠道恶性瘤的管理.
更多相关视频
08:53In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
相关概念视频
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
